Sho Hashimoto

12PUBLICATIONS
14CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical genetics (excl. cancer genetics)Molecular targetsObstetrics and gynaecology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Nov 22, 2024
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.

Satoru Taguchi, Taketo Kawai, Yoshiki Ambe

|Sep 23, 2023
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.

Satoru Taguchi, Taketo Kawai, Yoshiki Ambe

|May 25, 2023
Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer.

Hideaki Uchida, Daisuke Obinata, Shogo Takada

|Nov 07, 2022
Characteristics of prostate biopsy in patients under the dutasteride treatment.

Daisuke Obinata, Ken Nakahara, Tsuyoshi Yoshizawa

|Aug 23, 2022
Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020).

Satoru Taguchi, Taketo Kawai, Tohru Nakagawa

|Aug 12, 2022
Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy.

Daisuke Obinata, Daigo Funakoshi, Fuminori Sakurai

Pageof 2

Frequent Collaborators

4 joint publications

Daisuke Obinata

4 joint publications

Satoru Takahashi

3 joint publications

Satoru Taguchi

3 joint publications

Taketo Kawai